Are amikacin and gentamicin active against Pseudomonas aeruginosa, including multidrug‑resistant organisms?

Aminoglycoside Activity Against Pseudomonas aeruginosa

Both amikacin and gentamicin are active against Pseudomonas aeruginosa, but amikacin demonstrates superior efficacy, particularly against multidrug-resistant (MDR) strains, and should be preferentially selected when aminoglycoside therapy is indicated.

Activity Against Standard P. aeruginosa

Both aminoglycosides possess intrinsic activity against P. aeruginosa and are FDA-approved for this indication 1. Gentamicin has documented in vitro synergistic effects when combined with carbenicillin against many P. aeruginosa strains 1. However, when comparing the two agents directly:

• Amikacin is favored over gentamicin due to enhanced efficacy against non-fermenting gram-negative bacilli, including P. aeruginosa 2
• Clinical guidelines specifically recommend amikacin as the preferred aminoglycoside for late-onset hospital-acquired pneumonia where P. aeruginosa is suspected 2

Activity Against Multidrug-Resistant P. aeruginosa (MDRO)

The distinction between these agents becomes critical when treating resistant organisms:

Amikacin's Superior Performance

• Amikacin demonstrates the highest activity among aminoglycosides against gentamicin-resistant P. aeruginosa, with 97% susceptibility in some studies 3, 4
• Against gentamicin-resistant strains, amikacin exhibited the greatest activity alongside carbenicillin, particularly against highly resistant isolates 4
• In MDR P. aeruginosa collections, amikacin showed 92% susceptibility compared to gentamicin's 94% resistance 5

Gentamicin's Limitations

• Gentamicin resistance is common in MDR P. aeruginosa, with resistance rates reaching 43-94% in various studies 5, 3, 6
• Cross-resistance between gentamicin, tobramycin, and netilmicin is frequent, but amikacin often retains activity 4, 6

Clinical Application for Difficult-to-Treat Resistance (DTR-PA)

For DTR-PA (defined as non-susceptibility to all first-line agents including carbapenems, cephalosporins, fluoroquinolones, and piperacillin-tazobactam):

First-line therapy should be novel β-lactam agents (ceftolozane-tazobactam, ceftazidime-avibactam) when susceptible 7. However, when these are unavailable or the organism is resistant:

• Aminoglycosides remain an option but should be used in combination therapy, not as monotherapy 8, 9
• For severe DTR-PA infections susceptible only to older agents, treatment with two in vitro active drugs is suggested 8
• Amikacin is the aminoglycoside of choice when this class is selected 2

Important Caveats

1. Aminoglycoside monotherapy is contraindicated for P. aeruginosa pneumonia or bloodstream infections 9

2. Combination therapy indications:

   • Patients in septic shock or high risk of death (>25% mortality risk) should receive combination therapy with two active agents 9
   • Once septic shock resolves and susceptibilities are known, de-escalation to monotherapy is appropriate if a highly active β-lactam is available 9

3. Adjunctive inhaled aminoglycosides should be considered for VAP due to gram-negative bacilli susceptible only to aminoglycosides or polymyxins, using both inhaled and systemic routes 9

4. Nephrotoxicity monitoring is essential, as aminoglycosides carry significant renal toxicity risk, particularly in cirrhotic patients or those receiving concurrent nephrotoxic agents 10, 11

5. Recent guideline updates (CLSI 2023) suggest limiting aminoglycoside use to urinary isolates, requiring cautious evaluation for systemic P. aeruginosa infections 12

Practical Algorithm

For empiric therapy when P. aeruginosa is suspected:

• Use antipseudomonal β-lactam PLUS amikacin (not gentamicin) if combination therapy is warranted 2

For targeted therapy based on susceptibilities:

• If susceptible to novel β-lactams → use monotherapy with ceftolozane-tazobactam or ceftazidime-avibactam 7
• If resistant to all first-line agents but susceptible to aminoglycosides → use amikacin in combination with another active agent 8
• Never use aminoglycoside monotherapy for serious infections 9